A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

IonQ (NYSE:IONQ) made headlines with the first known simulation of neutrinoless double-beta decay using its quantum computer, highlighting groundbreaking scientific achievements that suggest quantum ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

In all, their investment portfolio pulled in an estimated 54% return in 2024, more than double the S&P 500’s 25% gain — and ...

The UK's FTSE 100 saw its five-week winning streak halted, influenced by global tensions between Israel and Iran, and ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

The lawsuit stems from last month's report that claimed Tempus overstates its AI capabilities and engages in "aggressive ...